MedTrace Logo

Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

NCT02146378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-02-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to understand safety (e.g., occurrence of adverse drug reactions \[ADRs\]) and efficacy data on the long-term use of Vyndaqel Capsules (hereinafter referred to as Vyndaqel) in all patients who received this drug under actual use conditions after its marketing.

Conditions

  • Transthyretin Familial Amyloid Polyneuropathy

Interventions

DRUG

Vyndaqel

20mg/day

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-10
Primary Completion
2023-03-10
Completion
2023-03-10
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146378 on ClinicalTrials.gov